1. Home
  2. |Insights
  3. |Bill Requiring White House to Provide Sequestration Specifics Moves Forward

Bill Requiring White House to Provide Sequestration Specifics Moves Forward

Client Alert | less than 1 min read | 07.27.12

Following bipartisan passage (414-2) in the House on July 18, the Senate on Wednesday passed the Sequestration Transparency Act of 2012 requiring OMB to prepare a report for Congress within 30 days identifying each account to be sequestered and the resulting reductions at the program, project, and activity level; itemizing all exempt accounts; and providing any other data and explanations necessary to enhance public understanding of the sequester. While the Administration initially opposed the Act, press reports now indicate that the President will likely sign the bill into law.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights